-
Publication Venue For
-
Response to: "How to communicate in science" by Klareskog et al.
2019
-
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.
2019
-
Response to: 'Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities' by Bossuyt et al..
78:e77.
2019
-
Response to: 'Comment on editorial 'Pathogenic effector functions of ACPA: where do we stand'' by Holmdahl.
2019
-
Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups..
78:996-1002.
2019
-
Pathogenic effector functions of ACPA: Where do we stand?.
78:716-721.
2019
-
Response to: 'Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center study' by Pregnalato et al..
78:e51.
2019
-
Response to: 'Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?' by Meroni et al..
78:e47.
2019
-
Response to: 'Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis' by van Hoovels et al..
78:e49.
2019
-
Unexpected link between mitochondrial DNA and T cell help in systemic lupus erythematosus..
78:e59.
2019
-
Response to 'Antinuclear antibodies by indirect immunofluorescence and solid phase assays' by Bossuyt et al.
2019
-
Response to: 'Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler..
78:e34.
2019
-
Response to: 'Postpartum breastfeeding status' by Betzold..
78:e38.
2019
-
Response to: 'Can solid-phase assays replace immunofluorescence for ANA screening?' by Bizzaro.
2019
-
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts..
78:122-130.
2019
-
Response to: "Antinuclear autoantibodies: discordance among four different assays" by Pacheco et al.
2018
-
Response to: 'ANA testing in "real life"' by Infantino etal.
2018
-
Role of Epstein-Barr virus infection in SLE: gene-environment interactions at the molecular level..
77:1249-1250.
2018
-
Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE..
77:911-913.
2018
-
Effects of immune checkpoint inhibitors on B cells: relationship to immune-related adverse events..
77:795-796.
2018
-
How the gut inflames the joints..
77:634-635.
2018
-
Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors..
77:612-619.
2018
-
Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research..
77:241-250.
2018
-
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups..
76:1955-1964.
2017
-
Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study..
76:1890-1896.
2017
-
EULAR recommendations for disease management: guidance not guidelines..
76:935-938.
2017
-
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative..
76:782-791.
2017
-
Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)..
76:811-820.
2017
-
The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission..
76:855-861.
2017
-
International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials..
76:673-680.
2017
-
Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression..
76:612-619.
2017
-
Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium..
76:186-195.
2017
-
Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis..
75:1757-1762.
2016
-
Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells..
75:1858-1865.
2016
-
Longitudinal validation of periarticular bone area and 3D shape as biomarkers for knee OA progression? Data from the FNIH OA Biomarkers Consortium..
75:1607-1614.
2016
-
Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups..
75:1558-1566.
2016
-
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions..
75:1428-1437.
2016
-
Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type..
75:1166-1169.
2016
-
Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol..
75:1074-1080.
2016
-
Bone loss, pain and inflammation: three faces of ACPA in RA pathogenesis..
75:637-639.
2016
-
Dietary fatty acid content regulates wound repair and the pathogenesis of osteoarthritis following joint injury..
74:2076-2083.
2015
-
2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative..
74:1789-1798.
2015
-
Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein..
73:557-566.
2014
-
The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?.
73:336-348.
2014
-
Value of biomarkers in osteoarthritis: current status and perspectives..
72:1756-1763.
2013
-
Long-term safety of pegloticase in chronic gout refractory to conventional treatment..
72:1469-1474.
2013
-
Predictors of preterm birth in patients with mild systemic lupus erythematosus..
72:1536-1539.
2013
-
Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis..
72:1342-1350.
2013
-
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis..
72:686-693.
2013
-
Increased susceptibility of Trpv4-deficient mice to obesity and obesity-induced osteoarthritis with very high-fat diet..
72:300-304.
2013
-
Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies..
70:1713-1718.
2011
-
Clinical, radiographic, molecular and MRI-based predictors of cartilage loss in knee osteoarthritis..
70:1223-1230.
2011
-
Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations..
69:856-861.
2010
-
Change in regional cartilage morphology and joint space width in osteoarthritis participants versus healthy controls: a multicentre study using 3.0 Tesla MRI and Lyon-Schuss radiography..
69:155-162.
2010
-
Association of bone scintigraphic abnormalities with knee malalignment and pain..
68:1673-1679.
2009
-
Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing..
68:1535-1540.
2009
-
The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study..
68:1613-1617.
2009
-
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study..
68:805-811.
2009
-
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade..
68:823-827.
2009
-
Precision of 3.0 Tesla quantitative magnetic resonance imaging of cartilage morphology in a multicentre clinical trial..
67:1683-1688.
2008
-
Head-to-head comparison of the Lyon Schuss and fixed flexion radiographic techniques. Long-term reproducibility in normal knees and sensitivity to change in osteoarthritic knees..
67:1562-1566.
2008
-
Joint-specific hand symptoms and self-reported and performance-based functional status in African Americans and Caucasians: The Johnston County Osteoarthritis Project..
66:1622-1626.
2007
-
Effect of pregnancy on disease flares in patients with systemic lupus erythematosus.
2018
-
Establishment of reference intervals for osteoarthritis-related soluble biomarkers: the FNIH/OARSI OA Biomarkers Consortium.
2017